Paper32207804
Nonalcoholic Steatohepatitis: A Review.
Sheka AC and 5 others. JAMA, 2020. Cited by 1,195 papers, by iCite.
Cite this record
ConductScience Library. Nonalcoholic Steatohepatitis: A Review. Papers, record 32207804. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32207804
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Liver | Major topic |
| Non-alcoholic Fatty Liver Disease | Major topic |
| Bariatric Surgery | |
| Diagnosis, Differential | |
| Disease Progression | |
| Humans | |
| Life Style | |
| Liver Cirrhosis | |
| Metabolic Syndrome | |
| Obesity | |
| Prevalence | |
| United States |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R21 DK122832 | NIDDK NIH HHS | United States | R21DK122832 | PubMed and NIH |
Source NIH RePORTER
Trials5
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04626492 | Quantitative MRI Imaging in Diffuse Liver Diseases | Background | ClinicalTrials.gov | |
| NCT06097338 | Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFF | Background | ClinicalTrials.gov | |
| NCT06334666 | The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With MASLD. | Results | ClinicalTrials.gov | |
| NCT06826807 | Hepatic Elastography-Enhanced Lifestyle Modification in MASLD | Background | ClinicalTrials.gov | |
| NCT07513922 | The Correlation Between hs CRP TG Triglycerides Glucose Index in NAFLD and Liver Fibrosis | Results | ClinicalTrials.gov |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 32343314 | Typographical Error. | https://conductscience.org/library/papers/32343314 | PubMed |
| Comment in | 32870291 | Nonalcoholic Steatohepatitis. | https://conductscience.org/library/papers/32870291 | PubMed |
Cited by779
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,195 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42989347 | TUDCA was identified as a potential therapeutic drug for nonalcoholic steatohepatitis complicated with hypercholesterolemia targeting ADRA2C by integrated bioinformatics and experimental verification. | Biol Direct | 2026 | https://conductscience.org/library/papers/42989347 | PubMed |
| 42985147 | Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment. | EXCLI J | 2026 | https://conductscience.org/library/papers/42985147 | PubMed |
| 42959101 | A multicohort proteomics-based machine learning score (MASHPredict) for noninvasive diagnosis and long-term prognostication of metabolic dysfunction-associated steatohepatitis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42959101 | PubMed |
| 42958058 | Effects of bariatric surgery on non-invasive markers of MASLD: a retrospective analysis. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/42958058 | PubMed |
| 42947668 | From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42947668 | PubMed |
| 42927671 | Diet-induced obesity enhances the glycaemic response to glucagon in male C57BL/6J mice. | Exp Physiol | 2026 | https://conductscience.org/library/papers/42927671 | PubMed |
| 42882529 | Targeting Gut Microbiota, Inflammation, and Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: Therapeutic Strategies and the Emerging Role of Time-Restricted Feeding. | Cells | 2026 | https://conductscience.org/library/papers/42882529 | PubMed |
| 42846764 | Differential Associations of Dietary Inflammatory Index and Dietary Antioxidant Indices With Mortality Risk From MASLD/MetALD: Results From a Large Population-Based Study. | Food Sci Nutr | 2026 | https://conductscience.org/library/papers/42846764 | PubMed |
| 42763838 | Ovarian tumor domain-containing protein 1 deficiency attenuates metabolic dysfunction-associated steatotic liver disease by promoting the ubiquitination of HSP90α in hepatocytes. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42763838 | PubMed |
| 42694403 | Shenling Baizhu powder alleviates non-alcoholic steatohepatitis by reducing PPARα-mediated NLRP3 inflammasome activation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42694403 | PubMed |
| 42650052 | High Prevalence of Protective HSD17B13 Variant in Taiwan: An Analysis in Morbidly Obese Individuals and Liver Donors. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42650052 | PubMed |
| 42596894 | Associations between physical activity and dietary live microbe intake with non-alcoholic fatty liver disease: findings from the NHANES, 2007-2018. | J Glob Health | 2026 | https://conductscience.org/library/papers/42596894 | PubMed |
| 42572603 | Endogenous phosphatidylcholine 16:0/20:4 increases to promote liver regeneration in hepatectomy. | iScience | 2026 | https://conductscience.org/library/papers/42572603 | PubMed |
| 42566528 | TRIM29-dependent AKR1B10 degradation ameliorates MASH. | Sci Adv | 2026 | https://conductscience.org/library/papers/42566528 | PubMed |
| 42564158 | Natural polysaccharides as immunometabolic modulators in metabolic diseases: mechanisms and translational challenges. | Front Immunol | 2026 | https://conductscience.org/library/papers/42564158 | PubMed |
| 42558980 | Resmetirom Ameliorates Fibrogenesis in Hepatic Stellate Cells via Thyroid Hormone Receptor Alpha-Fatty-Acid Amide Hydrolase 1 Signaling Pathway. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42558980 | PubMed |
| 42518348 | Panax notoginseng saponins alleviates metabolic dysfunction-associated steatotic liver disease in mice by influencing Nrf2/MT2. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42518348 | PubMed |
| 42506440 | Mitochondrial Dysfunction in Metabolic-Syndrome-Related MASLD/MASH: Metabolic Mechanisms and Therapeutic Perspectives. | Metabolites | 2026 | https://conductscience.org/library/papers/42506440 | PubMed |
| 42483986 | Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany. | J Comp Eff Res | 2026 | https://conductscience.org/library/papers/42483986 | PubMed |
| 42471585 | A combi-elasto ultrasound based deep learning model on liver fibrosis staging for suspected MASLD/MASH patients. | BMC Med Imaging | 2026 | https://conductscience.org/library/papers/42471585 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32207804
GET https://conductscience.org/api/papers/v1/32207804/cited_by?page=2